Revolution Medicines revenue and financials
$199.87Change from previous close: −3.76%Absolute change: −$7.81
Fiscal year ending in December. Sources and method on the page Methodology and sources.
Financial data
Amounts in millions of USD; per-share values in USD; shares in millions.
| Item | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Total assets | 4,323 | 2,254 | 2,355 | 2,252 | 2,430 | 2,365 | 2,558 | 1,763 | 1,808 | 1,908 | 2,062 | 984 |
| Current assets | 4,028 | 1,968 | 2,075 | 1,977 | 2,176 | 2,135 | 2,328 | 1,579 | 1,625 | 1,729 | 1,879 | 824 |
| Cash and equivalents | 815 | 441 | 384 | 217 | 402 | 334 | 543 | 201 | 276 | 288 | 696 | 358 |
| Short-term investments | 3,123 | 1,467 | 1,642 | 1,714 | 1,735 | 1,769 | 1,746 | 1,348 | 1,315 | 1,415 | 1,157 | 455 |
| Receivables | — | — | — | — | — | — | — | — | — | — | 1.3 | 0.3 |
| Net property, plant and equipment | 162 | 161 | 165 | 167 | 147 | 143 | 142 | 99.2 | 101 | 99.9 | 100 | 73.4 |
| Goodwill | 14.6 | 14.6 | 14.6 | 14.6 | 14.6 | 14.6 | 14.6 | 14.6 | 14.6 | 14.6 | 14.6 | 14.6 |
| Other intangible assets | 55.8 | 55.8 | 55.8 | 55.9 | 56.1 | 56.4 | 56.7 | 56.9 | 57.2 | 57.5 | 57.7 | 58.0 |
| Current liabilities | 354 | 290 | 290 | 246 | 185 | 159 | 164 | 111 | 105 | 93.7 | 144 | 85.5 |
| Accounts payable | 88.4 | 80.5 | 64.6 | 74.8 | 56.8 | 47.5 | 54.4 | 24.5 | 29.3 | 32.4 | 61.8 | 29.6 |
| Long-term debt | 1,036 | 281 | 268 | 257 | 245 | — | — | — | — | — | — | — |
| Total debt | 642 | 157 | 159 | 158 | 133 | — | — | — | — | — | — | — |
| Total liabilities | 1,717 | 754 | 723 | 655 | 564 | 287 | 293 | 197 | 190 | 183 | 236 | 147 |
| Total equity (incl. minority) | 2,606 | 1,500 | 1,631 | 1,597 | 1,865 | 2,078 | 2,265 | 1,566 | 1,619 | 1,725 | 1,826 | 837 |
| Retained earnings | -3,967 | -3,323 | -2,869 | -2,504 | -2,199 | -1,951 | -1,738 | -1,543 | -1,387 | -1,254 | -1,138 | -976 |